Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s blockbuster Dupixent. Last year, BMS reported a phase 3 trial in eosinophilic ...

Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading ...

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6 ...

PHILADELPHIA – Josh Myers couldn’t have picked a worse way to venture into his uncertain future, even if the Green Bay Packers center felt he “got lucky” Sunday. “I thought I broke my leg,” Myers said ...

Add center Josh Myers to the list. Myers suffered a devastating leg injury late in the fourth quarter with the Packers trailing 22-10 in what turned out to be their final offensive possession of ...

Source: FactSet Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet ...

BMS-986368 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate ...

Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to GlobalData, Phase II drugs for Anaplastic Large ...